FDA Beats Alvogen Suit Over Xifaxan Skinny Label Rejection
The U.S. Food and Drug Administration was within its right to bar an Alvogen unit from launching its trimmed-down version of Salix's blockbuster drug Xifaxan based on its interpretation of a...To view the full article, register now.
Already a subscriber? Click here to view full article